Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2025 Financial Results Life Science Investing
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement Life Science Investing
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease Conference 2025 Life Science Investing
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease Conference 2025 Life Science Investing
Exelixis to Webcast Virtual 2025 Research & Development Day on Wednesday, December 10, 2025 Life Science Investing
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Future Market Opportunities Life Science Investing
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation Life Science Investing
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date Life Science Investing
New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025 Confirms Pharmacological Effect of LEQEMBI® on Neurotoxic A? Protofibrils in CSF Life Science Investing
New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025 Confirms Pharmacological Effect of LEQEMBI® on Neurotoxic A? Protofibrils in CSF Life Science Investing
